Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CAPS NASDAQ:NMTR NYSE:OGEN NASDAQ:PTPI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCAPSCapstone Therapeutics$1.36-2.9%$1.67$1.29▼$16.18$221K-0.8107,639 shs39,307 shsNMTR9 Meters Biopharma$0.00+∞$0.00$0.07▼$6.56$3K1.36315,915 shs9,884 shsOGENOragenics$1.31-0.8%$2.61$1.23▼$75.60$1.08M0.65342,663 shs115,597 shsPTPIPetros Pharmaceuticals$0.03-6.9%$0.03$0.02▼$16.25$841K1.565.36 million shs811,915 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCAPSCapstone Therapeutics-2.86%-18.56%-4.23%-22.73%+135,999,900.00%NMTR9 Meters Biopharma0.00%-99.72%-99.72%-99.72%-81.82%OGENOragenics-0.76%+1.55%-14.94%-75.74%-95.27%PTPIPetros Pharmaceuticals-8.16%-1.82%-15.09%-78.40%-99.70%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCAPSCapstone TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANMTR9 Meters BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AOGENOragenics0.1391 of 5 stars0.04.00.00.00.00.00.0PTPIPetros PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCAPSCapstone Therapeutics 0.00N/AN/AN/ANMTR9 Meters Biopharma 0.00N/AN/AN/AOGENOragenics 0.00N/AN/AN/APTPIPetros Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCAPSCapstone Therapeutics$43.42M0.00N/AN/A($19.40) per share-0.07NMTR9 Meters BiopharmaN/AN/AN/AN/A$0.19 per shareN/AOGENOragenicsN/AN/AN/AN/A$0.61 per shareN/APTPIPetros Pharmaceuticals$5.11M0.16N/AN/A$4.04 per share0.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCAPSCapstone Therapeutics-$2.56MN/A0.00∞N/AN/AN/AN/AN/ANMTR9 Meters Biopharma-$43.77M-$3.46N/A∞N/AN/A-584.97%-159.45%N/AOGENOragenics-$20.66M-$33.63N/A∞N/AN/A-2,087.95%-486.56%N/APTPIPetros Pharmaceuticals-$8.16M-$60.87N/A∞N/AN/A-78.22%-23.50%N/ALatest CAPS, NMTR, OGEN, and PTPI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025PTPIPetros PharmaceuticalsN/A-$8.46N/A-$9.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCAPSCapstone TherapeuticsN/AN/AN/AN/AN/ANMTR9 Meters BiopharmaN/AN/AN/AN/AN/AOGENOragenicsN/AN/AN/AN/AN/APTPIPetros PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCAPSCapstone Therapeutics0.281.140.47NMTR9 Meters BiopharmaN/A0.590.59OGENOragenicsN/A1.931.93PTPIPetros Pharmaceuticals1.580.850.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCAPSCapstone Therapeutics2.55%NMTR9 Meters Biopharma22.34%OGENOragenics18.71%PTPIPetros Pharmaceuticals12.34%Insider OwnershipCompanyInsider OwnershipCAPSCapstone Therapeutics42.80%NMTR9 Meters Biopharma2.40%OGENOragenics4.90%PTPIPetros Pharmaceuticals12.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCAPSCapstone Therapeutics38158,00090,000N/ANMTR9 Meters Biopharma2014.34 million13.99 millionNo DataOGENOragenics5823,00010.98 millionN/APTPIPetros Pharmaceuticals2031.16 million9.93 millionNot OptionableCAPS, NMTR, OGEN, and PTPI HeadlinesRecent News About These CompaniesPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company ...June 26, 2025 | finanznachrichten.dePetros Pharmaceuticals to deconsolidate subsidiary to improve financesJune 26, 2025 | investing.comPetros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity Position | MorningstarJune 26, 2025 | morningstar.comMPetros Pharmaceuticals, Inc. (PTPI) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comPetros Pharmaceuticals Inc News (PTPI) - Investing.comJune 26, 2025 | investing.comPetros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity PositionJune 25, 2025 | accessnewswire.comAPetros Pharmaceuticals to appeal Nasdaq delisting decisionMay 23, 2025 | uk.investing.comPetros Pharmaceuticals Announces Transition from NASDAQ to OTC MarketsMay 21, 2025 | accessnewswire.comAPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device DeveloperMay 20, 2025 | finanznachrichten.dePetros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device DeveloperMay 20, 2025 | accessnewswire.comAPetros Pharmaceuticals Strengthens Partnership with Market Leading Big Data Provider Implementing Key Enhancements to its AI PlatformMay 6, 2025 | accessnewswire.comAPetros Proprietary Technology Platform Aligns with April 15, 2025 President Trump Executive Order Advancing Rx-to-OTC Reclassification ReformsApril 29, 2025 | accessnewswire.comAPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple IndicationsMarch 20, 2025 | finanznachrichten.dePetros Pharmaceuticals enters collaboration with big data, analytics firmMarch 20, 2025 | msn.comPetros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple IndicationsMarch 20, 2025 | accessnewswire.comAPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal StudyFebruary 27, 2025 | finanznachrichten.dePetros Pharmaceuticals announces top-line results of expanded App Comp studyFebruary 25, 2025 | markets.businessinsider.comPetros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal StudyFebruary 25, 2025 | accessnewswire.comAPetros Pharmaceuticals prices 40M shares at 24c in public offeringFebruary 18, 2025 | markets.businessinsider.comPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and WarrantsFebruary 18, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the Horizon3 Bullish Biotech Stocks With Explosive Growth TrendsBy Chris Markoch | July 21, 2025View 3 Bullish Biotech Stocks With Explosive Growth TrendsAnalysts Make a Quantum Bet on D-Wave's Cryogenic Packaging By Nathan Reiff | August 4, 2025View Analysts Make a Quantum Bet on D-Wave's Cryogenic Packaging 3 Small Caps Drawing Insider and Institutional SupportBy Chris Markoch | July 14, 2025View 3 Small Caps Drawing Insider and Institutional SupportNew Catalyst Sends Joby Stock to 52-Week HighsBy Jeffrey Neal Johnson | July 15, 2025View New Catalyst Sends Joby Stock to 52-Week HighsCAPS, NMTR, OGEN, and PTPI Company DescriptionsCapstone Therapeutics NASDAQ:CAPS$1.36 -0.04 (-2.86%) As of 08/6/2025 03:59 PM EasternCapstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.9 Meters Biopharma NASDAQ:NMTR$0.0002 +0.00 (+∞) As of 08/4/20259 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.Oragenics NYSE:OGEN$1.31 -0.01 (-0.76%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$5.00 +3.69 (+281.68%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.Petros Pharmaceuticals NASDAQ:PTPI$0.03 0.00 (-6.90%) As of 08/6/2025 03:59 PM EasternPetros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Joby Deal Gives Blade New Direction, But Stock Lacks Lift How DigitalOcean's Focus Is Fueling Explosive Growth Disney’s Iger-Led Turnaround Gains Traction Can Celsius Stock Keep Its Momentum Going Any Longer? AMD’s Results Sparked a Sell-Off—But That’s Your Buy Signal Rivian Takes Earnings Hit—R2 Could Be the Stock's 2026 Lifeline Does Broadcom Have a VMware Problem? Goldman Eyes Upside in NTNX RSI Stock Soars 22% On Q2 Blowout—Will PENN Match the Momentum? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
